The U.S. Food and Drug Administration on Thursday granted 510(k) clearance for Becton, Dickinson and Company’s (NYSE:BDX) new breast biopsy system.

The FDA approved BD’s EnCor EnCompass Breast Biopsy and Tissue Removal System, which is expected to hit the market in early 2026.

This system is designed to enhance the biopsy experience by allowing clinicians to perform procedures across various breast imaging modalities.

The EnCor EnCompass system features advanced capabilities, including high and low vacuum strengths, 360-degree sampling ability, and a choice of probes tailored for different lesion types.

Market Valuation and Performance Range

The company maintains a market capitalization of $59.10 billion. The stock’s 52-week range spans from $162.29 to $251.99.

This positive news comes during a day when major indices are also ...